UY39303A - Inhibidores de mutación her2 - Google Patents

Inhibidores de mutación her2

Info

Publication number
UY39303A
UY39303A UY0001039303A UY39303A UY39303A UY 39303 A UY39303 A UY 39303A UY 0001039303 A UY0001039303 A UY 0001039303A UY 39303 A UY39303 A UY 39303A UY 39303 A UY39303 A UY 39303A
Authority
UY
Uruguay
Prior art keywords
compounds
salts
her2 mutation
enantiomers
formula
Prior art date
Application number
UY0001039303A
Other languages
English (en)
Inventor
Erik James Hicken
Ellen Ruth Laird
Bradley Jon Newhouse
Spencer Phillip Pajk
Mark Laurence Boys
Bryan Daniel Ellis
John Joseph Gaudino
Nicholas Charles Lazzara
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of UY39303A publication Critical patent/UY39303A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I): (I),y enantiómeros de estos, y a sales farmacéuticamente aceptables de la fórmula (I) y dichos enantiómeros, en donde L1, L2, R1, R2, R3 y n son como se definen en el presente documento. La invención se refiere además a composiciones farmacéuticas que comprenden dichos compuestos y sales, y a métodos y usos de dichos compuestos, sales y composiciones para el tratamiento del crecimiento celular anormal, incluido el cáncer, en un sujeto que lo necesite.
UY0001039303A 2020-06-30 2021-06-29 Inhibidores de mutación her2 UY39303A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046506P 2020-06-30 2020-06-30
US202163208901P 2021-06-09 2021-06-09

Publications (1)

Publication Number Publication Date
UY39303A true UY39303A (es) 2022-01-31

Family

ID=76797050

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039303A UY39303A (es) 2020-06-30 2021-06-29 Inhibidores de mutación her2

Country Status (4)

Country Link
US (2) US11834453B2 (es)
TW (1) TW202214641A (es)
UY (1) UY39303A (es)
WO (1) WO2022003575A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ES2399427T3 (es) 2003-08-14 2013-04-01 Array Biopharma, Inc. Análogos de quinazolina como inhibidores de los receptores de la tirosina-quinasa
CN102887891B (zh) 2005-11-15 2016-03-09 阿雷生物药品公司 N4-苯基-喹唑啉-4-胺衍生物和相关化合物
WO2019042409A1 (zh) 2017-09-01 2019-03-07 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
DK3853220T3 (da) 2018-09-18 2024-03-04 Hoffmann La Roche Quinazolinderivater som antitumormidler
WO2021127397A1 (en) 2019-12-19 2021-06-24 Black Diamond Therapeutics, Inc. Nitrogen heterocyclic compounds and methods of use
WO2021156180A1 (en) * 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
WO2021156178A1 (en) * 2020-02-03 2021-08-12 Boehringer Ingelheim International Gmbh [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors
US11608343B2 (en) 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
US20230265098A1 (en) 2020-07-02 2023-08-24 Enliven Therapeutics, Inc. Alkyne quinazoline derivatives as inhibitors of erbb2
PE20240327A1 (es) 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
WO2022266458A1 (en) 2021-06-17 2022-12-22 Black Diamond Therapeutics, Inc. 6-heterocycloalkyl-quinazoline derivatives and uses thereof
IL309252A (en) 2021-06-26 2024-02-01 Array Biopharma Inc Inhibitors of HER2 mutations

Also Published As

Publication number Publication date
US11834453B2 (en) 2023-12-05
WO2022003575A1 (en) 2022-01-06
US20230023851A1 (en) 2023-01-26
TW202214641A (zh) 2022-04-16
US20240124474A1 (en) 2024-04-18

Similar Documents

Publication Publication Date Title
UY38553A (es) Inhibidores de cdk2
NI201900013A (es) Inhibidor de piridopirimidinona cdk2/4/6
UY38196A (es) Inhibidores de cinasa dependientes de ciclina
CO2021017504A2 (es) Derivados de benzisoxazol sulfonamida
DOP2023000281A (es) Inhibidores de mutación de her2
CO2022016377A2 (es) Inhibidores de kras tricíclicos fusionados
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
ECSP22077299A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades asociadas con modulación del pi3k
ECSP15031579A (es) Lactamas Fusionadas de Arilo y Heteroarilo
CO6710897A2 (es) Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer
GT201200242A (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6
UY39193A (es) Compuestos de azalactama como inhibidores de hpk1
ECSP23083562A (es) Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades
UY39517A (es) Inhibidores de la btk
CL2022003716A1 (es) Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida
CO2024001285A2 (es) Compuestos tricíclicos como inhibidores de kras
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
UY39303A (es) Inhibidores de mutación her2
DOP2022000203A (es) 3-fenoxiazetidin-1-il-pirazinas sustituidas con actividad antagonista gpr52
AR122805A1 (es) Inhibidores de mutación her2
EA202191818A1 (ru) 3-карбониламино-5-циклопентил-1h-пиразольные соединения, обладающие ингибирующей активностью в отношении cdk2
AR126238A1 (es) Inhibidores de mutación de her2
MX2020004871A (es) Derivados de acido cafeico y sus usos.